Companies should list suggested retail prices of drugs in direct-to-consumer ads, says AMA

The USA’s largest association of physicians and medical students has proposed a series of policies to promote more transparency in drug pricing to protect patients.

One policy adopted by the American Medical Association’s (AMA) at its annual meeting last week calls on manufacturers to list the suggested retail prices of drugs when running direct-to-consumer adverts.

Naloxone, an off-patent drug used to reverse the effects of opioid overdose, is cited in an AMA statement as an example of a much-needed drug which has become ‘inexplicably expensive’.